Achieve Life SciencesSTU:SP4P -3.60%32 PB Ratio is 30.92 as of Jul. 12, 2026, which is 77200% above its 10-year median of 0.04. GuruFocus rates STU:SP4P with a GF Score™ of 32/100. The stock has 4 warning signs investors should review. Among 1,231 Biotechnology companies, Achieve Life Sciences ranks worse than 94.96% on this metric.
Achieve Life Sciences Inc stock PB Ratio (=30.4) is close to 10-year high of 30.4.
The historical rank and industry rank for Achieve Life Sciences's PB Ratio or its related term are showing as below:
STU:SP4P'
s PB Ratio Range Over the Past 10 Years
Min: 0.01 Med: 0.04 Max: 30.4
Current: 30.4
During the past 13 years, Achieve Life Sciences's highest PB Ratio was 30.40. The lowest was 0.01. And the median was 0.04.
STU:SP4P's PB Ratio is ranked worse than 94.96% of 1231
companies
in the Biotechnology industry
Industry Median: 2.93
vs STU:SP4P: 30.40
During the past 12 months, Achieve Life Sciences's average Book Value Per Share Growth Rate was -32.10% per year.
During the past 3 years, the average Book Value Per Share Growth Rate was -4.50% per year.
During the past 13 years, the highest 3-Year average Book Value Per Share Growth Rate of Achieve Life Sciences was 29.30% per year. The lowest was -79.80% per year. And the median was -37.85% per year.
Back to Basics: PB Ratio
Achieve Life Sciences (STU:SP4P) PB Ratio Explanation
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Achieve Life Sciences's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Achieve Life Sciences PB Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Achieve Life Sciences's PB Ratio distribution charts can be found below:
* The bar in red indicates where Achieve Life Sciences's PB Ratio falls into.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
Achieve Life Sciences (STU:SP4P) has a PB Ratio of 30.92 as of Jul. 12, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Achieve Life Sciences and its competitors. This is 77200% above median its historical median of 0.04. Over the past decade, Achieve Life Sciences' PB Ratio has ranged from 0.01 to 30.40. According to the industry distribution chart, Achieve Life Sciences ranks #1169 out of 1231 companies in the Biotechnology industry, placing it in the top 95%.
Is Achieve Life Sciences' PB Ratio too high?
Achieve Life Sciences' current PB Ratio of 30.92 is 77200% above median its 10-year median of 0.04. Over the past 10 years, this metric has ranged from a low of 0.01 to a high of 30.40. The Biotechnology industry median PB Ratio is 2.93. Achieve Life Sciences' value of 30.92 is 955.3% above this industry median. Based on the distribution chart, Achieve Life Sciences ranks #1169 out of 1231 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Achieve Life Sciences has a GF Score™ of 32/100, reflecting its overall financial health beyond just this single metric.
How does Achieve Life Sciences' PB Ratio compare to STTK and CRMD?
According to the Biotechnology industry distribution chart, Achieve Life Sciences ranks #1169 out of 1231 companies for PB Ratio. This places Achieve Life Sciences in the lower half of its industry. The industry median PB Ratio is 2.93. Achieve Life Sciences' value of 30.92 is 955.3% above this benchmark. Historically, Achieve Life Sciences' own PB Ratio has ranged from 0.01 to 30.40 over the past decade. While the company's 10-year median is 0.04 vs. the industry median of 2.93, Achieve Life Sciences has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Biotechnology company?
The median PB Ratio among Biotechnology companies is 2.93, based on 1,231 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Achieve Life Sciences's current PB Ratio of 30.92 is 955.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Achieve Life Sciences and its competitors. For the Biotechnology industry, the median PB Ratio is 2.93 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Achieve Life Sciences's current PB Ratio is 30.92, which is 77200% above median its own 10-year median of 0.04. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Achieve Life Sciences stock overvalued right now?
Achieve Life Sciences (STU:SP4P) has a current PB Ratio of 30.92. The current PB Ratio is 30.92, which is 77200% above median its 10-year median of 0.04 and 955.3% above the Biotechnology industry median of 2.93. Achieve Life Sciences' overall GF Score™ is 32/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For Achieve Life Sciences (STU:SP4P), the current PB Ratio is 30.92 as of Jul. 12, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Achieve Life Sciences Inc is a late-stage clinical specialty pharmaceutical company with the sole mission to address the nicotine dependence epidemic through the development and commercialization of cytisinicline. Cytisinicline, is a naturally occurring alkaloid. Additionally, The company has completed a Phase 2 study with cytisinicline in vaping cessation and conducted a successful end-of-Phase 2 meeting with the FDA for a future vaping indication. It operates in one operating segment, development and commercialization of cytisinicline for nicotine dependence, with operations located in Canada, the United States and the U.K.
32GF Score
Get the complete analysis for STU:SP4P
PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:SP4P has been successfully added to your 
